Pretreatment with Drotaverine Hydrochloride before endoscopic retrograde cholangiopanc reatogra-phy: a prospective multicenter randomized controlled trial
10.3760/cma.j.issn.1007-5232.2009.08.002
- VernacularTitle:盐酸屈他维林在ERCP术前应用价值的多中心随机对照试验
- Author:
Peng WANG
;
Feng LIU
;
Jianfeng YANG
;
Chaoying FANG
;
Xiufen TANG
;
Chunlan ZHU
;
Xiao ZHANG
;
Liping HE
;
Xu REN
;
Zhaoshen LI
- Publication Type:Journal Article
- Keywords:
Cholangiopancreatography,endoscopic retrograde;
Scopolamine;
Drotaverine
- From:
Chinese Journal of Digestive Endoscopy
2009;26(8):397-401
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effects of drotaverine hydrochloride versus scopolamine in re-ducing duodenal motility and in facilitating cannulation during endoscopic retrograde cholangiopancreatogra-phy (ERCP). Methods Randomized controlled trial of 650 participants from 4 endoscopic centers assigned to receive scopolamine 20 mg or drotaverine hydrochloride 40 mg intravenously 15 minutes before ERCP. Pa-rameters including duodenal motility grades, success rates of deep cannulation, ERCP-related complications and adverse effects were recorded. Results The data of 638 patients (319 in each group) were valid. There were no significant differences in duodenal motility grades (1.17 ±0. 82 vs. 1.13 ± 0.89, P =0. 705), success rate of deep cannulation (90. 9% vs. 91.8%, P =0. 672) and incidence of ERCP-related complications (11.3% vs. 11.0%, P =0. 900) between 2 groups. However, the incidence of tachycardia (heart rate > 120 bpm) during ERCP was lower in drotaverine group than in scopolamine group (2. 2% vs. 6. 9%, P = 0. 004). There was no significant difference in other adverse effects (nausea, vomiting) between 2 groups. Conclusion Drotaverine hydrochloride may provide a reasonable alternative as antimotility agent before ERCP.
